LAS VEGAS, June 2, 2020 /PRNewswire/ -- Diabetic Peripheral Neuropathy Market will increase because of the rising global burden of diabetes that is driving prevalence of diabetic neuropathy, advancement in early diagnosis as well as launch of the promising therapies which will positively impact DPN market.

DelveInsight added a new report titled "Diabetic Peripheral Neuropathy MarketInsights, Epidemiology, and Market Forecast-2030" to its portfolio.

Key Highlights from Diabetic Peripheral Neuropathy Market report are:

Request for sample pages to know more onDiabetic Peripheral Neuropathy Epidemiology and Market Forecast

Diabetic Peripheral Neuropathy is a painful condition that is caused by nerve damage from diabetes. It is a common prevalent complication in neurological damage of Type 1 and Type 2 diabetes.

There is a huge patient population pool affected by the disease; the Diabetic Peripheral Neuropathy market report covers the disease epidemiology that is segmented into Total Diagnosed Prevalent Cases of DPN, Total Prevalent Cases of Painful DPN and Gender-specific Prevalent cases of DPN in the 7MM from 2017 to 2030.

The total Painful Diabetic Peripheral Neuropathy Prevalent Cases were 3,857,945 in the United States in 2020. Also, females are more affected by the disease as compared to males for Diabetic Peripheral NeuropathyPrevalent in the US in 2020.

Click here to know more onDiabetic Peripheral Neuropathypipeline

Among the 7MM, the US accounts for 58% of the overall market size of DPN. Among the EU-5 countries, Germany accounts for the highest market size for DPN. Diabetic Peripheral Neuropathy market has a diverse pipeline with several promising therapies. Also, Gene therapy has been developed for DPN pain management. Of the emerging therapies, the most anticipated product to get launched is VM202 Apart from this, other products include VM202 (Helixmith), NYX-2925 (Aptinyx), WST-057 (4% pirenzepine) (WinSanTor, Inc.), Ricolinostat (Regenacy Pharmacuticals), NRD.E1 (Novaremed Ltd.), Cebranopadol (Grnenthal GmbH), GRC 17356 (Glenmark Pharmaceuticals), and others are also expected to enter the market by 2030 as effective therapies. The potential launch of these emerging drugs will aid in overall market growth. There are a couple of market drivers which will be driving the market. One such factor will be an early diagnosis of the DPN because of the advancements happening in the DPN diagnostic approaches. As the patient pool for diabetic peripheral neuropathy is quite large, and there is no treatment for reversal of disease, this indication withholds a plethora of opportunities for drug development companies. No doubt that the clinical pipeline contains a large number of drugs; however, previously multiple clinical trial failures gave a setback and limited the research and development in the DPN domain. So far it has been clear that path traversed is not easy in DPN research as the long-term clinical trials and low success rate in meeting the clinical endpoints may become threats for the investors to fund further.

There aremany key players robustly involved in developing potential drugs and they are a ray of hopefor DPN patients such as:1. VM2022. NYX-29253. WST-0574. Ricolinostat5. ISC 175366. NRD135S.E17. Cebranopadol8. GRC 173569. MEDI735210. Trazodone/GabapentinAnd many others

The key players involved in Diabetic Peripheral Neuropathy market are:1. Helixmith2. Aptinyx3. WinSanTor, Inc4. Regenacy Pharmacuticals5. Ichnos Science6. Novaremed7. Grnenthal GmbH8. Glenmark Pharmaceuticals9. AstraZeneca10. AngeliniAnd many others

The reasons for buying Diabetic Peripheral Neuropathy market report:

Table of contents

1. Key Insights

2. Executive summary

3. Diabetic Peripheral Neuropathy Market Overview at a Glance

4. Diabetic Peripheral Neuropathy Epidemiology and Market Methodology

5. Diabetic Peripheral Neuropathy Disease Background and Overview

6. Diabetic Peripheral Neuropathy Epidemiology and Patient Population

6.1. Key Findings

6.2. Total Diagnosed Prevalent cases of Diabetic Peripheral Neuropathy in 7MM

6.3. United States

6.4. EU5

6.5. Germany

6.6. France

6.7. Italy

6.8. Spain

6.9. United Kingdom

6.10. Japan

7. Diabetic Peripheral Neuropathy Treatment and Management

8. Diabetic Peripheral Neuropathy Unmet need

9. Diabetic Peripheral Neuropathy Marketed Drugs

9.1. Key cross competition

9.2. Qutenza: Grnenthal

9.3. Tarlige: Daiichi Sankyo

10. Diabetic Peripheral Neuropathy Emerging drugs

10.1. Key cross competition

10.2. VM202: Helixmith

10.3. NYX-2925: Aptinyx

10.4. WST-057: WinSanTor

10.5. Ricolinostat: Regenacy Pharmaceuticals

10.6. Cebranopadol: Grnenthal

10.7. ISC 17536: Ichnos Science

10.8. NRD135S.E1: Novaremed

10.9. MEDI7352: AstraZeneca

10.10. Trazodone/Gabapentin: Angelini

11. Diabetic Peripheral Neuropathy Market Size

11.1. Key Findings

11.2. Total Market Size of Painful Diabetic Peripheral Neuropathy in 7MM

11.3. Diabetic Peripheral Neuropathy Market Outlook: 7 MM

11.4. United States

11.5. EU5

11.6. Germany

11.7. France

11.8. Italy

11.9. Spain

11.10. United Kingdom

11.11. Japan

12. Diabetic Peripheral Neuropathy Reimbursement policies

13. Market Drivers

14. Market Barriers

15. SWOT Analysis

16. KOL Views

17. Diabetic Peripheral Neuropathy Case Report

18. A Case Report of Diabetic Peripheral Neuropathy

19. Bibliography

20. Appendix

21. Diabetic Peripheral Neuropathy Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

Request a WebEx Demo to get a walk-through of the Diabetic Peripheral Neuropathy Market Report:https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-market

Related Reports:

Diabetic Peripheral Neuropathy Epidemiology Forecast-2030 report delivers an in-depth understanding of the disease, historical, forecasted epidemiology trends of DPN in the 7 MM.

Diabetic Peripheral Neuropathy Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Diabetic Peripheral Neuropathy market.

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.

Contact us:

Shruti Thakurinfo@delveinsight.com+91-9650213330DelveInsight

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

Continued here:
Diabetic Peripheral Neuropathy Market is Expected to Increase with a CAGR of 12% for the Study Period of 2017-2030: DelveInsight - P&T Community

Comments are closed.